U.S. markets open in 8 hours 24 minutes
  • S&P Futures

    4,123.00
    -23.25 (-0.56%)
     
  • Dow Futures

    33,981.00
    -202.00 (-0.59%)
     
  • Nasdaq Futures

    13,236.25
    -109.75 (-0.82%)
     
  • Russell 2000 Futures

    2,183.00
    -20.30 (-0.92%)
     
  • Crude Oil

    65.33
    +0.05 (+0.08%)
     
  • Gold

    1,830.40
    -5.70 (-0.31%)
     
  • Silver

    27.50
    -0.17 (-0.62%)
     
  • EUR/USD

    1.2129
    -0.0024 (-0.19%)
     
  • 10-Yr Bond

    1.6240
    0.0000 (0.00%)
     
  • Vix

    21.84
    +2.18 (+11.09%)
     
  • GBP/USD

    1.4121
    -0.0023 (-0.17%)
     
  • USD/JPY

    108.8330
    +0.2130 (+0.20%)
     
  • BTC-USD

    57,385.24
    +2,020.17 (+3.65%)
     
  • CMC Crypto 200

    1,553.09
    +1,310.41 (+539.98%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    27,889.86
    -718.73 (-2.51%)
     

DiaMedica Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and CEO, will deliver a corporate presentation at B. Riley’s Neuroscience Investor Conference on Thursday, April 29th at 11:30am ET. DiaMedica will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley.

The recorded presentation will be available on the Investors section of the Company’s website at https://www.diamedica.com/investors/events-presentations beginning Thursday, April 29th.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, visit www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005062/en/

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

For Investor Inquiries:
Tim McCarthy
Managing Director, LifeSci Advisors, LLC
tim@lifesciadvisors.com